Results 81 to 90 of about 24,516 (282)

Detection of the United States Neisseria meningitidis urethritis clade in the United Kingdom, August and December 2019 - emergence of multiple antibiotic resistance calls for vigilance. [PDF]

, 2020
Since 2015 in the United States (US), the US Neisseria meningitidis urethritis clade (US_NmUC) has caused a large multistate outbreak of urethritis among heterosexual males.
Borrow, R, Brooks, A, Campbell, H, Campbell, L, Fifer, H, Gray, S, Hughes, G, Ladhani, SN, Lekshmi, A, Lucidarme, J, Ramsay, ME, Rayment, M, Schembri, G   +12 more
core   +2 more sources

United States clinical practice experience with eculizumab in myasthenia gravis: symptoms, function, and immunosuppressant therapy use

Journal of Neurology
The phase 3 REGAIN study and its open-label extension demonstrated the efficacy of the complement C5 inhibitor eculizumab in patients with treatment-refractory, acetylcholine receptor antibody–positive generalized myasthenia gravis (gMG).
Ali A. Habib, Andrew Klink, Srikanth Muppidi, A. Parthan, S. C. Sader, A. Balanean, A. Gajra, Richard J. Nowak, James F. Howard   +8 more
semanticscholar   +1 more source

Proteomic Analysis of Golden Sputum Reveals Pulmonary Complement Activation During Acute Chest Syndrome in Children With Sickle Cell Disease

American Journal of Hematology, EarlyView.
ABSTRACT Acute chest syndrome (ACS) is one of the most common severe complications of sickle cell disease (SCD). In recent years, a major role of inflammation and innate immunity has been evidenced, but ACS pathophysiology remains incompletely understood, and therapeutic options are limited.
Slimane Allali, Nabiha Sbeih, Rachel Rignault‐Bricard, Johanna Bruce, Morgane Le Gall, Claire Heilbronner, Noemie de Cacqueray, Sofia Angyalosy, Melissa Taylor, Joséphine Brice, Mariane de Montalembert, Martina Bevacqua, Emilie‐Fleur Gautier, Olivier Hermine, Thiago Trovati Maciel   +14 more
wiley   +1 more source

US Clinical Practice Experience with Eculizumab in Myasthenia Gravis: Acute Clinical Events and Healthcare Resource Utilization

Drugs - Real World Outcomes
Background and Objective The terminal complement inhibitor eculizumab is approved in the USA for the treatment of patients with acetylcholine receptor antibody-positive generalized myasthenia gravis (MG).
Richard J. Nowak, Ali A. Habib, Andrew J. Klink, Srikanth Muppidi, Anju Parthan, S. Chloe Sader, Alexandrina Balanean, Ajeet Gajra, James F. Howard, ELEVATE Study Group   +9 more
doaj   +1 more source

Analysis of Costs per Responder in US Adults with Paroxysmal Nocturnal Hemoglobinuria with a Suboptimal Response to Prior Eculizumab Treatment

Hematology Reports, 2023
European Society for Blood and Marrow Transplantation (EBMT) hematologic response categories comprehensively assess complement inhibitor responses in patients with paroxysmal nocturnal hemoglobinuria (PNH).
Jesse Fishman, Seri Anderson, Sandra E. Talbird, David Dingli   +3 more
doaj   +1 more source

Myelitis‐Predominant Aggressive Phenotype: Unveiling Unique Patterns of Late‐Onset Neuromyelitis Optica Spectrum Disorders

Annals of Neurology, EarlyView.
Objective The objective of this study was to compare clinical features and prognosis of late‐onset neuromyelitis optica spectrum disorder (LO‐NMOSD, onset age ≥60 years) with adult‐onset NMOSD (AO‐NMOSD, onset age 18–59 years), and to provide insights for individualized management in elderly patients.
Ya‐Lan Pu, Jin‐Zhou Feng, Hua‐Xing Meng, Hai‐Bing Xiao, Xiao‐Ling Li, Jin Zhen, Wen‐Ying Lu, Xu‐Ming Xi, Ti Wu, Bao‐Shi Yuan, Mo‐Li Fan, Chao Zhang, De‐Cai Tian, Xia Meng, Fu‐Dong Shi, Tian Song   +15 more
wiley   +1 more source

Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland [PDF]

, 2017
Factor H autoantibodies can impair complement regulation, resulting in atypical hemolytic uremic syndrome, predominantly in childhood. There are no trials investigating treatment, and clinical practice is only informed by retrospective cohort ...
Almond, M, Awan, A, Booth, C, Brocklebank, V, Finlay, E, Fitzpatrick, M, Gilbert, RD, Goodship, TH, Hegde, S, Inward, C, Johnson, S, Kaur, A, Kavanagh, D, Kerecuk, L, Kinoshita, M, Marchbank, KJ, Marks, SD, Salama, AD, Sheerin, NS, Sheerin, TP, Tyerman, K, Walsh, PR, Webb, N, Wong, EKS   +23 more
core   +1 more source

Long-Term Efficacy and Safety of Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria and High Disease Burden: Real-World Data From Korea

Journal of Korean medical science, 2023
Background Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematologic disorder characterized by uncontrolled terminal complement activation. Eculizumab, a monoclonal antibody C5 inhibitor was introduced in Korea in 2009 and has been the standard ...
Jin Seok Kim, J. Jang, Deog-Yeon Jo, Seo-Yeon Ahn, S. Yoon, Je-Hwan Lee, Sung-Hyun Kim, Chul Won Choi, Ho-Jin Shin, Min-Kyoung Kim, Jae Hoon Lee, Y. Mun, J. Kong, BokJin Hyun, HyunSun Nam, Eunhye Kim, Min Joo Kwak, Yong Kyun Won, Jong Wook Lee   +18 more
semanticscholar   +1 more source

Distinct effects of complement C4A and C4B copy number in Systemic Sclerosis serological and clinical subtypes

Arthritis &Rheumatology, Accepted Article.
Objective Complement component 4 (C4), encoded by C4A and C4B within the major histocompatibility complex (MHC) on chromosome 6, regulates the immune response and clears immune complexes. Variable copy number (CN) of C4 genes and retroviral HERV‐K element influence its function.
Javier Martínez‐López, Carlos Rangel‐Peláez, Inmaculada Rodriguez‐Martin, Alfredo Guillen‐Del‐Castillo, Carmen P Simeón‐Aznar, José L Callejas, International SSc Group; PRECISESADs Clinical Consortium, Oliver Distler, Susanna M Proudman, Mandana Nikpour, Australian Scleroderma Interest Group (ASIG), Nicolas Hunzelmann, Gianluca Moroncini, Jeska K de Vries‐Bouwstra, Ariane L Herrick, Yannick Allanore, Marta E. Alarcon‐Riquelme, Lorenzo Beretta, Shervin Assassi, Christopher P Denton, Maureen D Mayes, Javier Martin, Marialbert Acosta‐Herrera, Martin Kerick   +23 more
wiley   +1 more source

Successful Pregnancies During Ongoing Eculizumab Therapy in Two Patients With Complement-Mediated Thrombotic Microangiopathy

Kidney Medicine, 2020
In patients with pregnancy-associated complement gene variant–mediated thrombotic microangiopathy (cTMA), terminal complement blockade is used for treatment of cTMA flares during pregnancy or following delivery.
Natalja Haninger-Vacariu, Christof Aigner, Renate Kain, Zoltán Prohászka, Martina Gaggl, Georg A. Böhmig, Leah Charlotte Piggott, Raute Sunder-Plassmann, Gere Sunder-Plassmann, Alice Schmidt   +9 more
doaj   +1 more source